Savella and Multiple sclerosis - a phase IV clinical study of FDA data

Summary:

Multiple sclerosis is reported as a side effect among people who take Savella (milnacipran hydrochloride), especially for people who are female, 40-49 old, have been taking the drug for 10+ years also take Topamax, and have Migraine.

The phase IV clinical study analyzes which people have Multiple sclerosis when taking Savella. It is created by eHealthMe based on reports of 6,561 people who have side effects when taking Savella from the FDA, and is updated regularly.

What is Savella?

Savella has active ingredients of milnacipran hydrochloride. It is often used in fibromyalgia. eHealthMe is studying from 7,529 Savella users. Check the latest studies of Savella.

What is Multiple sclerosis?

Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,085 drugs and 1,365 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.

On Aug, 11, 2026

6,561 people reported to have side effects when taking Savella.
Among them, 22 people (0.34%) have Multiple sclerosis.

Among these 22 people:

How long have people been on Savella when they have Multiple sclerosis? *

What is the gender of people who have Multiple sclerosis when taking Savella? *

female: 100 %
male: 0.0 %

What is the age of people who have Multiple sclerosis when taking Savella? *

What are other drugs people take besides Savella? *

What are other side effects people have besides Multiple sclerosis? *

Headache (pain in head): 8 people, 36.36%
Joint Pain: 7 people, 31.82%
Pain In Extremity: 7 people, 31.82%
Peripheral Swelling: 7 people, 31.82%
Cardiac Disorder: 7 people, 31.82%
Fatigue (feeling of tiredness): 6 people, 27.27%
Sleep Apnea Syndrome: 5 people, 22.73%
Sneezing: 4 people, 18.18%
Intervertebral Disc Protrusion (spinal disc protrusion): 4 people, 18.18%
Glucose Urine Present: 4 people, 18.18%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 7 people, 31.82%
Migraine (headache): 7 people, 31.82%
Diabetes: 6 people, 27.27%
Nerve Block (the interruption of signals travelling along a nerve): 4 people, 18.18%
Gastric Disorder (disease of stomach): 4 people, 18.18%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 18.18%
High Blood Pressure: 4 people, 18.18%
Insomnia (sleeplessness): 4 people, 18.18%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 4 people, 18.18%
Raynaud's Phenomenon (discoloration of the fingers, toes, and occasionally other areas): 4 people, 18.18%

* Approximation only. Some reports may have incomplete information.

Do you take Savella and have Multiple sclerosis?

- Check whether Multiple sclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Savella:

Savella (7,529 reports)

Browse all side effects of Savella:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Multiple sclerosis:

Multiple sclerosis (1,085 drugs)

Browse all the conditions that are associated with Multiple sclerosis:

Multiple sclerosis (1,365 conditions)

Related publications that referenced our studies

Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on milnacipran hydrochloride (the active ingredients of Savella) and Savella (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.